Open AccessNiclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
Author(s) -
Anne Weiss,
Franck Touret,
Cécile Baronti,
Magali Gilles,
Bruno Hoën,
Antoine Nougairède,
Xavier de Lamballerie,
Morten Otto Alexander Sommer
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0260958
Subject(s) - niclosamide , potency , covid-19 , beta (programming language) , pharmacology , virology , alpha (finance) , biology , medicine , in vitro , biochemistry , ecology , construct validity , nursing , disease , patient satisfaction , computer science , infectious disease (medical specialty) , programming language
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.